This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

Vesugen

Emerging

Khavinson tripeptide (Lys-Glu-Asp / KED) marketed as a "vascular bioregulator." Mechanism is thin (one DNA-binding-style hypothesis, same…

Aliases (8)

Vesugen · KED peptide · KED tripeptide · Lys-Glu-Asp · Vezugen · ВЕЗУГЕН · Vesilute (sometimes) · KED-tripeptide-bioregulator

TYPICAL DOSE

200 mg/cap

Daily

ROUTE

Subcutaneous injection

Subcutaneous / IM

CYCLE

20-30 days on, every 4-6 months. Canonical Khav…

Typical duration

STORAGE

Store -20°C dry, dark, before reconstitution

Refrigerated

Overview

What is Vesugen?

Vesugen is a synthetic short-chain peptide (Lys-Glu-Asp, KED) developed by Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is part of a class of "peptide bioregulators" researched in Russia for vascular aging and longevity.

Key Benefits

May support vascular endothelial health, normalize blood pressure, reduce vascular aging markers in older adults (per Russian peptide research), and improve overall cardiovascular tone.

Mechanism of Action

Khavinson peptides are proposed to enter the cell nucleus and modulate gene expression directly, binding chromatin and influencing transcription of tissue-specific repair and regeneration genes. For Vesugen, the proposed targets are vascular endothelial cells regulating vasomotor tone and endothelial repair.

Molecular Information

Length

3 amino acids

Type

Tripeptide

Amino Acid Sequence:

Lys-Glu-Asp

▸ Reconstitution Lyophilized peptide

Reconstitute lyophilized peptide with bacteriostatic water (BAC) using sterile technique. Calculator below converts vial mg + diluent mL into syringe units.

Vial size

20 mg / vial

Steps

1 Wipe BAC water vial + peptide vial stoppers with isopropyl alcohol.
2 Draw the planned diluent volume into a 1 mL syringe.
3 Inject diluent slowly down the inside wall of the peptide vial — do NOT spray onto powder.
4 Swirl gently (do not shake) until fully dissolved. Solution should be clear.
5 Label vial with date reconstituted; refrigerate 2-8 °C.
6 Use within 30 days for most peptides (BPC-157 / TB-500 ~ 60 days at 4 °C).

Open dose calculator for Vesugen

Peptide Interactions

epithalon

Synergistic

co-administered partner in some "vascular + pineal" longevity protocols. Theoretical only; no head-to-head data showing additive benefit.

pinealon

Synergistic

same originating group, sometimes paired in "brain + vascular" longevity framings. Running multiple Khavinson short peptides simultaneously stacks the same s…

the canonical stack antioxidant base

Synergistic

(NAC, curcumin, astaxanthin, vitamin C) — likely additive if anything, no interaction concern.

Other Khavinson tripeptides simultaneously

Avoid

(EDR/Pinealon, AED/Cerluten, Cortagen, etc.) — running multiple at once makes attribution impossible and stacks the single-source-evidence problem. Pick one …

Quality Indicators

✓

White, fluffy cake (peptides)

Lyophilized peptide should appear as a white, fluffy "cake" filling most of the vial bottom. Indicates proper freeze-drying.

✓

Clear solution after reconstitution

After mixing with bacteriostatic water, the solution should be crystal clear with no particles or cloudiness.

Slight clumping acceptable

Small clumps that fully dissolve with gentle swirling are normal — shipping can cause minor compaction.

✗

Collapsed or melted powder

Powder that looks collapsed, melted, or stuck to vial sides may have been heat-damaged in transit.

✗

Cloudy or particulate solution

Persistent cloudiness or visible particles after gentle mixing indicate degraded or contaminated material.

What to Expect

Day 1-7
Injection / administration protocol established. Tolerability check.
Week 2-4
Early onset of effect — subtle in most users, noticeable in responders.
Week 4-8
Peak benefit window for most peptide cycles.
Week 8+
Cycle decision point: continue, taper, or break.

Side Effects & Safety

Common (>10%): None reliably above placebo background.
Less common (1-10%): Mild headache during initiation, vivid dreams / altered sleep, mild GI discomfort (oral), injection-site reaction (injectable). Same profile as pinealon.
Rare-serious (<1%): Allergic reaction to peptide / excipients. No documented organ toxicity in available preclinical literature; no documented dependence; no withdrawal syndrome. "No known signal" rather than "definitively safe" — assay portfolio is small and from interested parties.
Specific watch periods: None established — but treat first 1-2 weeks of any cycle as initiation-monitoring window.
Theoretical concerns: Same pro-survival / pro-regeneration class concern as pinealon — theoretical contraindication during active or prior malignancy. Not personally relevant for users in this archetype.